Abbott Laboratories (ABT) said Monday new results from a trial showed that the TriClip transcatheter edge-to-edge repair system to treat leaky heart valves provided "substantial and sustained improvements" in the severity of the condition after two years.
The data also showed that that the device significantly reduced the rate of heart failure hospitalizations and improved the quality of life of patients, the company said.
Abbott shares were slightly higher in recent trading.
Price: 131.81, Change: +0.99, Percent Change: +0.76
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。